9 Feb 2009 07:00

Notification of Award of Options to PuriCore Directors and PDMRsÂ
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 9 February 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely and effectively kill infectious pathogens, today announces that on 6 February 2009 options in the Company were granted to the Executive Director, Non-Executive Directors, and Persons Discharging Managerial Responsibility (PDMRs) under the terms of the PuriCore plc 2006 Executive Omnibus Incentive Plan.
The options to the Executive Director, Non-Executive Directors, and PDMRs (set out below) are to vest upon the achievement of performance conditions, are exercisable from the date of vesting until the fifth anniversary of the date of grant, and were awarded at an exercise price of 10 pence per share. The performance conditions allow that 50% of the options will vest upon achieving a closing stock price of 20 pence sustained for 90 trading days, and the remaining 50% of the options will vest upon achieving earnings per share of $0.05 in any fiscal year. Both performance targets must be met by 31 December 2011.
| Executive Director | Position | Options Granted | Total Options Held |
| Gregory Bosch | Chief Executive Officer | 2,400,000 | 7,756,100 |
| Director | Position | Options Granted | Total Options Held |
| Christopher Wightman | Non-Executive Chairman | 1,200,000 | 5,530,000 |
| Timothy Anderson | Non-Executive Director | 120,000 | 261,000 |
| Joseph William Birkett | Senior Independent Director | 150,000 | 460,000 |
| Michael Sapountzoglou | Non-Executive Director | 120,000 | 430,000 |
| James Walsh, PhD | Non-Executive Director | 150,000 | 291,000 |
| PDMR | Position | Options Granted | Total Options Held |
| Daniel Bee | President, International & UK Managing Director | 700,000 | 1,025,000 |
| David Correale | Vice President, Marketing and Business Development | 425,000 | 955,000 |
| Thomas Daniel | Senior Vice President and General Manager, Sterilox Food Safety | 425,000 | 1,305,000 |
| Andrea Drucker | Senior Vice President, General Counsel, and Company Secretary | 425,000 | 1,005,000 |
| Raymond Mannion | Vice President, Operations | 425,000 | 1,005,000 |
| Darren Weiss | Vice President, Finance | 425,000 | 910,000 |
The current issued ordinary share capital of the Company is 216,499,628.Â
Â
Enquiries:
| Ben  Brewerton | Greg Bosch, CEO | |
| Susan Quigley | Darren Weiss, VP Finance | |
| Financial  Dynamics |
| PuriCore |
| +44Â (0) 20Â 7831Â 3113 | +1Â 484Â 321Â 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.Â
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release